August 28, 2012
Samantha Lynn Inc. Recalls Reumofan Plus Tablets Due to Undeclared Drug Ingredients
The Missouri Department of Health and Senior Services received information regarding the recall of 500 lots of Reumofan Plus Tablets because of containing methocarbamol and diclofenac. Use of this product could result in life-threatening hypersensitivity reactions and anaphylaxis and could cause a temporary and reversible increase in CNS depression.
The product is used as a treatment for muscle pain, arthritis, osteoporosis, bone cancer and other conditions. The affected Reumofan Plus lots may include the following lot number(s): 99515 ex096 and expires: 2016. The product is marketed in a green bottle containing 30 lavender round tablets and is distributed nationwide via the internet.
The full recall information can be found at www.fda.gov/Safety/Recalls/ucm317114.htm?source=govdelivery.